Market Overview:
The global Parkinson's disease treatment market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of Parkinson's disease, rising awareness about available treatments, and growing demand for better and more effective therapies. The global Parkinson's disease treatment market is segmented on the basis of type into levodopa/carbidopa, dopamine receptor agonists, MAO-inhibitors, COMT-inhibitors, anticholinergics, and other drugs. Levodopa/carbidopa is currently the most commonly used drug for treating Parkinson's disease and is expected to maintain its dominant position in the market during the forecast period. Dopamine receptor agonists are also widely used for treating this condition and are expected to experience high growth rates during the forecast period. On the basis of application, hospitals pharmacies accounted for majority share of revenue in 2017 owing to higher prescription rates as compared with retail pharmacies or online pharmacies.
Product Definition:
Parkinson's disease is a movement disorder that results from the death of dopamine-producing cells in the brain. It is characterized by tremor, rigidity, and slowed movements. There is no cure for Parkinson's disease, but there are treatments that can help improve symptoms. Treatment options include medications such as levodopa and dopamine agonists, surgery to implant a deep brain stimulator, and physical therapy. The goal of treatment is to improve quality of life by reducing symptoms and improving function.
Levodopa/carbidopa:
Levodopa/carbidopa is a drug combination used for the treatment of Parkinson's disease. It helps in increasing the amount of dopamine, which is a chemical messenger that controls movement, in the brain. The drug was first manufactured and sold as Sinemet by Bausch & Lomb Inc., but later it was sold under different brand names worldwide including Levodopa, Carbidopa and Revatio among others.
Dopamine Receptor Agonists:
Dopamine receptor agonists is a class of drug that modifies the biological response of target cells by binding to Dopamine Receptor (DR). The drugs in this class include L-DOPA, Sustiva and Avlona. These drugs are used for the treatment of Parkinson’s disease.
The dopamine receptor agonist works by increasing the release of dopamine in brain, which stimulates motor neurons to send signals to muscles.
Application Insights:
Based on application, the market is segmented into hospital pharmacies, retailer pharmacies and online pharmacies. The online pharmacy segment held the largest share of over 60% in 2017 owing to its convenience and ease of use. Patients with PD are often concerned about their ability to perform daily activities such as cooking, cleaning and hygiene due to fatigue caused by PD symptoms. This has led patients towards using this convenient mode of medication which was a major factor driving the growth of this segment during last few years.
The hospital pharmacy segment is expected to grow at fastest rate during forecast period owing to increasing awareness among people regarding treatment options available for them other than medications prescribed by their physicians at home or nearest hospitals which are easily accessible for picking up medicines from these locations thus driving demand for transportation services thereby impacting overall market growth positively in near future as well.
Regional Analysis:
North America dominated the global Parkinson's disease treatment market in 2017. The presence of key pharmaceutical companies, availability of effective drugs, and high healthcare expenditure are some factors attributing to its large share. In addition, increasing prevalence of neurodegenerative conditions is expected to drive regional growth over the forecast period. According to Parkinson's Foundation statistics in 2018, around 1 million people in U.
Growth Factors:
- Increasing incidence of Parkinson's disease
- Growing awareness about Parkinson's disease and its treatment options
- Rising demand for better and more effective therapies for Parkinson's disease
- Availability of government funding for research on Parkinson's disease
- Technological advancements in the field of Parkinson's disease treatment
Scope Of The Report
Report Attributes
Report Details
Report Title
Parkinson's Disease Treatment Market Research Report
By Type
Levodopa/carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics, Other Drugs
By Application
Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies
By Companies
Teva (Israel), Novartis AG (Switzerland), GSK (UK), AbbVie (US), Merck (US), Boehringer Ingelheim (Germany), Impax Laboratories (US), Lundbeck (Denmark), UCB (Belgium), Valeant Pharmaceuticals (Canada), Acadia (US), Sun Pharma (India), Wockhardt (India), Dr. Reddy's (India), Intas (India), US WorldMeds (US), Zydus Cadila (India), Cipla (India)
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
239
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Parkinson's Disease Treatment Market Report Segments:
The global Parkinson's Disease Treatment market is segmented on the basis of:
Types
Levodopa/carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics, Other Drugs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Teva (Israel)
- Novartis AG (Switzerland)
- GSK (UK)
- AbbVie (US)
- Merck (US)
- Boehringer Ingelheim (Germany)
- Impax Laboratories (US)
- Lundbeck (Denmark)
- UCB (Belgium)
- Valeant Pharmaceuticals (Canada)
- Acadia (US)
- Sun Pharma (India)
- Wockhardt (India)
- Dr. Reddy's (India)
- Intas (India)
- US WorldMeds (US)
- Zydus Cadila (India)
- Cipla (India)
Highlights of The Parkinson's Disease Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Levodopa/carbidopa
- Dopamine Receptor Agonists
- MAO-Inhibitors
- COMT-inhibitors
- Anticholinergics
- Other Drugs
- By Application:
- Hospital Pharmacies
- Retailer Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Parkinson's Disease Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no cure for Parkinson's Disease, but there are treatments that can help manage the symptoms. Treatment options may include medication, surgery, physical therapy and support groups.
Some of the major players in the parkinson's disease treatment market are Teva (Israel), Novartis AG (Switzerland), GSK (UK), AbbVie (US), Merck (US), Boehringer Ingelheim (Germany), Impax Laboratories (US), Lundbeck (Denmark), UCB (Belgium), Valeant Pharmaceuticals (Canada), Acadia (US), Sun Pharma (India), Wockhardt (India), Dr. Reddy's (India), Intas (India), US WorldMeds (US), Zydus Cadila (India), Cipla (India).
The parkinson's disease treatment market is expected to register a CAGR of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Parkinson's Disease Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Parkinson's Disease Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Parkinson's Disease Treatment Market - Supply Chain
4.5. Global Parkinson's Disease Treatment Market Forecast
4.5.1. Parkinson's Disease Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Parkinson's Disease Treatment Market Size (000 Units) and Y-o-Y Growth
4.5.3. Parkinson's Disease Treatment Market Absolute $ Opportunity
5. Global Parkinson's Disease Treatment Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Parkinson's Disease Treatment Market Size and Volume Forecast by Type
5.3.1. Levodopa/carbidopa
5.3.2. Dopamine Receptor Agonists
5.3.3. MAO-Inhibitors
5.3.4. COMT-inhibitors
5.3.5. Anticholinergics
5.3.6. Other Drugs
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Parkinson's Disease Treatment Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Parkinson's Disease Treatment Market Size and Volume Forecast by Application
6.3.1. Hospital Pharmacies
6.3.2. Retailer Pharmacies
6.3.3. Online Pharmacies
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Parkinson's Disease Treatment Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Parkinson's Disease Treatment Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Parkinson's Disease Treatment Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Parkinson's Disease Treatment Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Parkinson's Disease Treatment Demand Share Forecast, 2019-2026
9. North America Parkinson's Disease Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Parkinson's Disease Treatment Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Parkinson's Disease Treatment Market Size and Volume Forecast by Application
9.4.1. Hospital Pharmacies
9.4.2. Retailer Pharmacies
9.4.3. Online Pharmacies
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Parkinson's Disease Treatment Market Size and Volume Forecast by Type
9.7.1. Levodopa/carbidopa
9.7.2. Dopamine Receptor Agonists
9.7.3. MAO-Inhibitors
9.7.4. COMT-inhibitors
9.7.5. Anticholinergics
9.7.6. Other Drugs
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Parkinson's Disease Treatment Demand Share Forecast, 2019-2026
10. Latin America Parkinson's Disease Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Parkinson's Disease Treatment Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Parkinson's Disease Treatment Market Size and Volume Forecast by Application
10.4.1. Hospital Pharmacies
10.4.2. Retailer Pharmacies
10.4.3. Online Pharmacies
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Parkinson's Disease Treatment Market Size and Volume Forecast by Type
10.7.1. Levodopa/carbidopa
10.7.2. Dopamine Receptor Agonists
10.7.3. MAO-Inhibitors
10.7.4. COMT-inhibitors
10.7.5. Anticholinergics
10.7.6. Other Drugs
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Parkinson's Disease Treatment Demand Share Forecast, 2019-2026
11. Europe Parkinson's Disease Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Parkinson's Disease Treatment Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Parkinson's Disease Treatment Market Size and Volume Forecast by Application
11.4.1. Hospital Pharmacies
11.4.2. Retailer Pharmacies
11.4.3. Online Pharmacies
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Parkinson's Disease Treatment Market Size and Volume Forecast by Type
11.7.1. Levodopa/carbidopa
11.7.2. Dopamine Receptor Agonists
11.7.3. MAO-Inhibitors
11.7.4. COMT-inhibiors
11.7.5. Anticholinergics
11.7.6. Other Drugs
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Parkinson's Disease Treatment Demand Share, 2019-2026
12. Asia Pacific Parkinson's Disease Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Parkinson's Disease Treatment Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Parkinson's Disease Treatment Market Size and Volume Forecast by Application
12.4.1. Hospital Pharmacies
12.4.2. Retailer Pharmacies
12.4.3. Online Pharmacies
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Parkinson's Disease Treatment Market Size and Volume Forecast by Type
12.7.1. Levodopa/carbidopa
12.7.2. Dopamine Receptor Agonists
12.7.3. MAO-Inhibitors
12.7.4. COMT-inhibitors
12.7.5. Anticholinergics
12.7.6. Other Drugs
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Parkinson's Disease Treatment Demand Share, 2019-2026
13. Middle East & Africa Parkinson's Disease Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Parkinson's Disease Treatment Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Parkinson's Disease Treatment Market Size and Volume Forecast by Application
13.4.1. Hospital Pharmacies
13.4.2. Retailer Pharmacies
13.4.3. Online Pharmacies
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Parkinson's Disease Treatment Market Size and Volume Forecast by Type
13.7.1. Levodopa/carbidopa
13.7.2. Dopamine Receptor Agonists
13.7.3. MAO-Inhibitors
13.7.4. COMT-inhibitors
13.7.5. Anticholinergics
13.7.6. Other Drugs
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Parkinson's Disease Treatment Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Parkinson's Disease Treatment Market: Market Share Analysis
14.2. Parkinson's Disease Treatment Distributors and Customers
14.3. Parkinson's Disease Treatment Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Teva (Israel)
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Novartis AG (Switzerland)
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. GSK (UK)
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. AbbVie (US)
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Merck (US)
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Boehringer Ingelheim (Germany)
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Impax Laboratories (US)
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Lundbeck (Denmark)
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. UCB (Belgium)
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Valeant Pharmaceuticals (Canada)
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Acadia (US)
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Sun Pharma (India)
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Wockhardt (India)
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Dr. Reddy's (India)
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Intas (India)
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. US WorldMeds (US)
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. Zydus Cadila (India)
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. Cipla (India)
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
